P. Bono Et Al. , "Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials," CLINICAL GENITOURINARY CANCER , vol.14, no.5, pp.406-414, 2016
Bono, P. Et Al. 2016. Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. CLINICAL GENITOURINARY CANCER , vol.14, no.5 , 406-414.
Bono, P., Oudard, S., Bodrogi, I., Hutson, T. E., Escudier, B., Machiels, J., ... Thompson, J. A.(2016). Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. CLINICAL GENITOURINARY CANCER , vol.14, no.5, 406-414.
Bono, Petri Et Al. "Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials," CLINICAL GENITOURINARY CANCER , vol.14, no.5, 406-414, 2016
Bono, Petri Et Al. "Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials." CLINICAL GENITOURINARY CANCER , vol.14, no.5, pp.406-414, 2016
Bono, P. Et Al. (2016) . "Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials." CLINICAL GENITOURINARY CANCER , vol.14, no.5, pp.406-414.
@article{article, author={Petri Bono Et Al. }, title={Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials}, journal={CLINICAL GENITOURINARY CANCER}, year=2016, pages={406-414} }